WO2006066240A3 - Procede d'estimation de patients souffrant d'une leucemie myeloide aigue - Google Patents

Procede d'estimation de patients souffrant d'une leucemie myeloide aigue Download PDF

Info

Publication number
WO2006066240A3
WO2006066240A3 PCT/US2005/046100 US2005046100W WO2006066240A3 WO 2006066240 A3 WO2006066240 A3 WO 2006066240A3 US 2005046100 W US2005046100 W US 2005046100W WO 2006066240 A3 WO2006066240 A3 WO 2006066240A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
patient
myeloid leukemia
acute myeloid
therapy
Prior art date
Application number
PCT/US2005/046100
Other languages
English (en)
Other versions
WO2006066240A2 (fr
WO2006066240A8 (fr
Inventor
Mitch Raponi
Original Assignee
Veridex Llc
Mitch Raponi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veridex Llc, Mitch Raponi filed Critical Veridex Llc
Priority to MX2007007401A priority Critical patent/MX2007007401A/es
Priority to JP2007547020A priority patent/JP2008523822A/ja
Priority to CA002589055A priority patent/CA2589055A1/fr
Priority to BRPI0515794-3A priority patent/BRPI0515794A/pt
Priority to EP05854761A priority patent/EP1836313A4/fr
Priority to AU2005316291A priority patent/AU2005316291A1/en
Publication of WO2006066240A2 publication Critical patent/WO2006066240A2/fr
Publication of WO2006066240A8 publication Critical patent/WO2006066240A8/fr
Priority to IL183555A priority patent/IL183555A0/en
Publication of WO2006066240A3 publication Critical patent/WO2006066240A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
    • C12Q2565/50—Detection characterised by immobilisation to a surface
    • C12Q2565/501—Detection characterised by immobilisation to a surface being an array of oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

L'invention concerne des procédés pour traiter le cancer et notamment des cas hématologiques malins, des patients comprenant l'analyse des profils d'expression génique et/ou les marqueurs moléculaires d'un patient afin de déterminer le statut et/ou le pronostic du patient. L'invention concerne aussi des procédés pour effectuer des analyses lorsqu'un patient sans rechutes ou non réfractaire est susceptible de réagir à un traitement avec des inhibiteurs de farnésyl transférase (FTI) et, éventuellement, avec d'autres produits thérapeutiques. Les procédés sont aussi utiles pour surveiller une thérapie de patient et pour sélectionner un cours de thérapie. Des gènes modulés en réponse au traitement avec FTI sont utilisés dans la formulation des profils.
PCT/US2005/046100 2004-12-17 2005-12-19 Procede d'estimation de patients souffrant d'une leucemie myeloide aigue WO2006066240A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
MX2007007401A MX2007007401A (es) 2004-12-17 2005-12-19 Metodos para evaluar a pacientes con leucemia mieloide aguda.
JP2007547020A JP2008523822A (ja) 2004-12-17 2005-12-19 急性骨髄性白血病患者を評価するための方法
CA002589055A CA2589055A1 (fr) 2004-12-17 2005-12-19 Procede d'estimation de patients souffrant d'une leucemie myeloide aigue
BRPI0515794-3A BRPI0515794A (pt) 2004-12-17 2005-12-19 processos para avaliar pacientes com leucemia mielóide aguda
EP05854761A EP1836313A4 (fr) 2004-12-17 2005-12-19 Procede d'estimation de patients souffrant d'une leucemie myeloide aigue
AU2005316291A AU2005316291A1 (en) 2004-12-17 2005-12-19 Methods for assessing patients with acute myeloid leukemia
IL183555A IL183555A0 (en) 2004-12-17 2007-05-30 Methods for assessing patients with acute myeloid leukemia

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US63726504P 2004-12-17 2004-12-17
US60/637,265 2004-12-17
US67011605P 2005-04-11 2005-04-11
US60/670,116 2005-04-11
US74118005P 2005-12-01 2005-12-01
US60/741,180 2005-12-01

Publications (3)

Publication Number Publication Date
WO2006066240A2 WO2006066240A2 (fr) 2006-06-22
WO2006066240A8 WO2006066240A8 (fr) 2006-09-08
WO2006066240A3 true WO2006066240A3 (fr) 2008-07-17

Family

ID=36588648

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/046100 WO2006066240A2 (fr) 2004-12-17 2005-12-19 Procede d'estimation de patients souffrant d'une leucemie myeloide aigue

Country Status (9)

Country Link
EP (1) EP1836313A4 (fr)
JP (1) JP2008523822A (fr)
KR (1) KR20070099564A (fr)
AU (1) AU2005316291A1 (fr)
BR (1) BRPI0515794A (fr)
CA (1) CA2589055A1 (fr)
IL (1) IL183555A0 (fr)
MX (1) MX2007007401A (fr)
WO (1) WO2006066240A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100617467B1 (ko) * 2005-09-27 2006-09-01 디지탈 지노믹스(주) 급성 골수성 백혈병 환자의 항암제 치료 반응성 예측용마커
CN103555825B (zh) * 2007-01-31 2015-09-30 俄亥俄州立大学研究基金会 用于急性髓细胞白血病(aml)的诊断、预后和治疗的基于微rna的方法和组合物
EP2056110A1 (fr) * 2007-10-31 2009-05-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Biomarqueur pour prédire une réponse à un traitement par un anti-TNF-alpha
EP2272028A1 (fr) * 2008-04-25 2011-01-12 Koninklijke Philips Electronics N.V. Classification de données d'échantillon
US7736861B1 (en) * 2009-10-19 2010-06-15 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
WO2012007783A1 (fr) * 2010-07-13 2012-01-19 Institut Gustave Roussy Trousses et procédés de détection de la capacité à induire une mort cellulaire cancéreuse immunogène chez un patient
WO2011131246A1 (fr) * 2010-04-22 2011-10-27 Institut Gustave Roussy Composés et utilisations de ceux-ci pour induire la mort d'une cellule cancéreuse immunogène chez un sujet
EP3556870B9 (fr) 2010-07-27 2022-09-28 Genomic Health, Inc. Procédé d'utilisation de l'expression génique pour déterminer le pronostic du cancer de la prostate
KR101660322B1 (ko) * 2011-04-28 2016-09-29 아크레이 가부시키가이샤 ＮＰＭ1 유전자의 ｅｘｏｎ12 변이의 검출용 프로브 및 그 용도
KR101922761B1 (ko) * 2015-11-18 2018-11-27 가톨릭대학교 산학협력단 급성 골수성 백혈병 진단을 위한 ｃ―Ｋｉｔ 돌연변이 실시간 정량 ＰＣＲ 분석법 및 이의 이용

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BULLINGER ET AL.: "Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 350, no. 16, 15 April 2004 (2004-04-15), pages 1605 - 1616, XP002366030 *
GOLUB T.R. ET AL.: "Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring", SCIENCE, vol. 286, no. 5439, 15 October 1999 (1999-10-15), pages 531 - 537, XP002207658 *

Also Published As

Publication number Publication date
IL183555A0 (en) 2007-09-20
KR20070099564A (ko) 2007-10-09
WO2006066240A2 (fr) 2006-06-22
JP2008523822A (ja) 2008-07-10
EP1836313A4 (fr) 2010-06-30
MX2007007401A (es) 2007-10-08
CA2589055A1 (fr) 2006-06-22
BRPI0515794A (pt) 2008-08-05
WO2006066240A8 (fr) 2006-09-08
AU2005316291A1 (en) 2006-06-22
EP1836313A2 (fr) 2007-09-26

Similar Documents

Publication Publication Date Title
EP1612281A3 (fr) Evaluation de patients souffrant de leucémie myéloïde aiguë
WO2006066240A3 (fr) Procede d'estimation de patients souffrant d'une leucemie myeloide aigue
Kocarnik et al. Molecular phenotypes of colorectal cancer and potential clinical applications
WO2004111273A3 (fr) Marqueurs d'expression genique utilises en vue d'une reaction a des medicaments inhibiteurs de egfr
Sanders et al. Somatic mutations of signaling genes in non-small-cell lung cancer
Pu et al. PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy
WO2004071572A3 (fr) Marqueurs d'expression genique utilises en vue d'une reaction a des medicaments inhibiteurs de egfr
WO2004111641A3 (fr) Procedes de detection de cancer et de controle de progression de cancer
WO2003038129A3 (fr) Methodes d'evaluation et de traitement de la leucemie
WO2006074367A3 (fr) Procede permettant de predire et de reduire le risque de metastases du cancer du sein dans les poumons
WO2007079024A3 (fr) Septum comprenant au moins une caracteristique identifiable, des orifices d’acces comprenant celle-ci et procedes s’y rapportant
WO2004053066A3 (fr) Procedes pour identifier, evaluer et traiter des patients suivant une therapie d'inhibition de proteasome
WO2004086949A3 (fr) Marqueurs d'adn utilises dans la gestion du cancer
WO2007137187A3 (fr) Système et procédé destinés à déterminer une intervention médicale individualisée pour une pathologie
WO2006133325A3 (fr) Analyse d'echantillons de tissus entourant des tumeurs malignes
HK1070921A1 (en) Method for determining the expression level of glutathione-s-transferase pi
Gabrovska et al. Semaphorin–plexin signalling genes associated with human breast tumourigenesis
WO2002070750A3 (fr) Methodes permettant de determiner l'expression genique de la dihydropyrimidine deshydrogenase
WO2002057489A3 (fr) Methode permettant de determiner un schema chimiotherapeutique en fonction de l'expression de ercc1 et ts
Welch et al. Early progress in epigenetic regulation of endothelin pathway genes
WO2009003706A3 (fr) Procédés, trousses et composés pour la détermination d'une sensibilité à un traitement d'un trouble pathologique par épothilones
Gleeson et al. Somatic STK11 and concomitant STK11/KRAS mutational frequency in stage IV lung adenocarcinoma adrenal metastases
EP1502962A3 (fr) Procedés pour l'estimation et le traitment du cancer
WO2005113835A3 (fr) Kits et procedes pour identifier, evaluer, prevenir et soigner le cancer du sein
Lin et al. E‐cadherin promoter polymorphism (C‐160A) and risk of recurrence in patients with superficial bladder cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200580048402.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005316291

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 555400

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 183555

Country of ref document: IL

Ref document number: 2589055

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2005316291

Country of ref document: AU

Date of ref document: 20051219

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005316291

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007547020

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/007401

Country of ref document: MX

Ref document number: 1020077013783

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005854761

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005854761

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0515794

Country of ref document: BR